Sugi Predict

Sugi Predict / Compounds / SCHEMBL2383136

SCHEMBL2383136

SCHEMBL2383136

[CH]1CCC(Oc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 2/20 0.61
▸ SLC6A4 P31645 3/20 0.52
▸ SLC6A3 Q01959 3/20 0.52
▸ SLC6A2 P23975 2/20 0.52
▸ CARM1 Q86X55 1/20 0.45
▸ PRMT6 Q96LA8 1/20 0.45
▸ DRD2 P14416 3/20 0.41
▸ DRD4 P21917 3/20 0.41
▸ DRD3 P35462 3/20 0.41
▸ CHRNB4 P30926 2/20 0.41
▸ CHRNA3 P32297 2/20 0.41
▸ CHRNA7 P36544 2/20 0.41
▸ CHRNA10 Q9GZZ6 2/20 0.41
▸ CHRNA9 Q9UGM1 2/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PARP10 Q53GL7 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ DDB1 Q16531 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7795379 0.89 HRH1 (0.53) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL796490 0.86 HRH1 (0.65) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL1829827 0.86 HRH1 (0.65) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL29856 0.85 HRH1 (0.71) HRH1SLC6A4SLC6A3SLC6A2CARM1
Ammonia Solution, Strong SCHEMBL8081694 0.84 HRH1 (0.63) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL791816 0.84 HRH1 (0.63) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL11792902 0.84 HRH1 (0.63) HRH1SLC6A4SLC6A3SLC6A2CARM1
Ammonia Solution, Strong SCHEMBL8078606 0.83 HRH1 (0.68) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL21261765 0.83 HRH1 (0.57) HRH1SLC6A4SLC6A3SLC6A2CARM1
SCHEMBL4408794 0.81 HRH1 (0.50) HRH1SLC6A4SLC6A3SLC6A2CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 — — US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 — — WO disclosed
EP-2686313-B1 BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-02-03 — — EP disclosed
EP-2545047-B9 HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) PROBIODRUG AG (DE) 2015-06-10 — — EP disclosed
EP-2545047-B1 HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) PROBIODRUG AG (DE) 2014-04-23 — — EP disclosed
EP-2686313-A1 BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2014-01-22 — — EP disclosed
US-8530670-B2 Inhibitors PROBIODRUG AG (DE) 2013-09-10 — — US disclosed
US-8420828-B2 Inhibitors PROBIODRUG AG (DE) 2013-04-16 — — US disclosed
US-20040110790-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents SRI INTERNATIONAL 2004-06-10 — — US disclosed
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2004-02-12 — — US disclosed
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2003-12-11 — — US disclosed
WO-2003089423-A2 NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS SRI INTERNATIONAL (US) 2003-10-30 — — WO disclosed
US-6492364-B1 Triazolo and derivatives as chemokine inhibitors TORAY INDUSTRIES, INC. (JP) 2002-12-10 — — US disclosed
CN-1287117-A Cyclobutene derivatives, preparation method and therapeutic use thereof SANKYO CO (JP) 2001-03-14 — — CN disclosed
EP-1070703-A1 Cyclobutene derivatives Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
EP-1067130-A1 TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT TORAY INDUSTRIES, INC. (JP) 2001-01-10 — — EP disclosed
EP-0254078-B1 PYRAN DERIVATIVES BASF Aktiengesellschaft (DE) 1991-02-06 — — EP disclosed
EP-0254078-A1 Pyran derivatives BASF Aktiengesellschaft (DE) 1988-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 HRH1 1649/4885SLC6A4 3840/4885SLC6A3 2966/4885
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 HRH1 2013/4885SLC6A4 4090/4885SLC6A3 2990/4885
US-20040110790-A1 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents TEAD4, TEAD3, TEAD1 HRH1 1284/4885SLC6A4 3365/4885SLC6A3 1963/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 HRH1 596/4885SLC6A4 2817/4885SLC6A3 4040/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 HRH1 645/4885SLC6A4 4819/4885SLC6A3 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.